Massarelli, Erminia
Lam, Vincent K.
Parra, Edwin R.
Rodriguez-Canales, Jaime
Behrens, Carmen
Diao, Lixia
Wang, Jing
Blando, Jorge
Byers, Lauren A.
Yanamandra, Niranjan
Brett, Sara
Morley, Peter
Sharma, Padmanee
Allison, James
Wistuba, Ignacio I.
Heymach, John V.
Funding for this research was provided by:
National Cancer Institute (P30CA016672)
Article History
Received: 25 April 2019
Accepted: 21 November 2019
First Online: 16 December 2019
Ethics approval and consent to participate
: This study was approved by the MD Anderson Institutional Review Board.
: Not applicable.
: EM:• Advisory Committees – Genentech, Nektar Therapeutics• Honoraria – Astra Zeneca Pharmaceuticals, Merck & Co• Research Support – Pfizer, Astra Zeneca, Merck, BMS, GSK, and Tessa PharmaceuticalsVKL:• Advisory Committees – Takeda• Honoraria – Bristol Myers Squibb• Research Support – Guardant Health, Geneplus, Takeda, Adaptimmune.LAB:• Consulting – AstraZeneca, AbbVie, GenMab, BergenBio, Pharma Mar SA.• Research Support – AbbVie, AstraZeneca, GenMab, Tolero Pharmaceuticals, Sierra OncologyPS:• Consulting – Constellation, Jounce, Kite Pharma, Neon, BioAtla, Pieris, Oncolytics, Merck, Forty-Seven, Polaris, Apricity, Marker Therapeutics, Codiak, ImaginAB.• Shareholder – Jounce, Neon, Constellation, Oncolytics, BioAtla, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, ImaginAB• Royalties and Licensing fees – JounceJA:• Consulting – Jounce, Kite Pharma, Neon, Amgen, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, ImaginAB, Tvardi Therapeutics, TapImmune.• Shareholder – Jounce, Neon, Constellation, Oncolytics, BioAtla, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, ImaginAB, TapImmune• Royalties and Licensing fees – Jounce, Merck, & BMSIIW:• Honoraria – Genentech/Roche, Bristol-Myers Squibb, Astra Zeneca/Medimmune, HTG Molecular, Merck, GlaxoSmithKline, and MSD.• Research Support – Genentech, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, and 4DJVH:• Advisory Committees – AstraZeneca, Boehringer Ingelheim, Exelixis, Genentech, GSK, Guardant Health, Hengrui, Lilly, Novartis, Spectrum, EMD Serono, and Synta.• Research Support – AstraZeneca, Bayer, GlaxoSmithKline, Spectrum.• Royalties and Licensing fees – Spectrum.NY, SB, PM are employees and shareholders of GlaxoSmithKline.JRC is an employee of MedImmune.All other authors have no conflicts of interest to disclose.